HC Wainwright Reiterates Buy Rating for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVOGet Rating)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Friday, TipRanks reports. They presently have a $30.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 7.60% from the company’s previous close.

A number of other equities analysts have also recently weighed in on VIVO. StockNews.com cut shares of Meridian Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 20th. Zacks Investment Research cut shares of Meridian Bioscience from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 12th.

VIVO traded up $1.56 during trading on Friday, reaching $27.88. 6,064 shares of the company’s stock were exchanged, compared to its average volume of 434,901. The company’s fifty day moving average price is $26.14 and its 200-day moving average price is $23.34. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.60 and a current ratio of 3.85. Meridian Bioscience has a fifty-two week low of $17.00 and a fifty-two week high of $28.72. The firm has a market capitalization of $1.21 billion, a PE ratio of 19.77 and a beta of 0.34.

Meridian Bioscience (NASDAQ:VIVOGet Rating) last released its earnings results on Friday, May 6th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.18. Meridian Bioscience had a net margin of 18.34% and a return on equity of 18.79%. The firm had revenue of $111.23 million during the quarter, compared to analyst estimates of $99.55 million. Research analysts forecast that Meridian Bioscience will post 1.44 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of VIVO. Horan Securities Inc. bought a new stake in Meridian Bioscience in the 4th quarter valued at $33,000. Prospera Financial Services Inc bought a new stake in Meridian Bioscience in the 1st quarter valued at $42,000. Spire Wealth Management bought a new stake in Meridian Bioscience in the 4th quarter valued at $47,000. Captrust Financial Advisors lifted its position in Meridian Bioscience by 23.8% during the 1st quarter. Captrust Financial Advisors now owns 7,782 shares of the company’s stock worth $202,000 after buying an additional 1,495 shares in the last quarter. Finally, Hightower 6M Holding LLC bought a new stake in Meridian Bioscience during the 1st quarter worth about $207,000. 94.72% of the stock is currently owned by institutional investors and hedge funds.

About Meridian Bioscience (Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Featured Stories

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.